the aid library

LIST OPTIONS

Filter

9090

Uganda: THE NATIONAL DRUG POLICY AND AUTHORITY (PHARMACOVIGILANCE) REGULATIONS, 2014

The Government of Uganda The Uganda Gazette (2014) C2

Download (585)

View PDF (844)

Rwanda: MOH GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF HUMAN PHARMACEUTICAL PRODUCTS

Ministry of Health, Rwanda (2014) C2

These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M... more

Download (373)

View PDF (678)

Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy

World Health Organization WHO (2013) C_WHO

New criteria for classifying and diagnosing hyperglycaemia first detected during pregnancy have been accepted by a group of experts convened by WHO. These new criteria are an update of recommendations published by WHO in 1999

Download (237)

View PDF (261)

Contact tracing: Public health management of persons, including healthcare workers, having had contact with COVID-19 cases in the European Union -third update

European Centers for Disease Control and Prevention ECDC (2020) C_CDC

This document aims to help EU/EEA public health authorities in the tracing and management of persons, including healthcare workers, who had contact with COVID-19 cases. It outlines the key steps of contact tracing, including contact identification, listing and follow-up, in the context of the COVID-... more

Download (687)

View PDF (613)

National Guideline on conducting Patient Experience of Care Survey in Public Health Establishments

Dept. of Health South Africa (2017) C2

External Link

Antimicrobial Resistance: Challenges and Perspectives

Doyle, M.P.; G. H. Loneragan, H. M. Scott et al. (2006) C2

Comprehensive Reviews in Food Science and Food Safety, Vol.12 (2013) pp.234-248 In 2006, the Institute of Food Technologists (IFT) published an Expert Report entitled “Antimicrobial Resistance: Implications for the Food System” (IFT 2006). That report summarized current scientiﬁc knowledge pe... more

Download (291)

View PDF (507)

Nutritional interventions update: multiple micronutrient supplements during pregnancy

World Health Organization WHO (2020) C_WHO

The World Health Organization’s comprehensive antenatal care (ANC) guideline WHO recommendations on antenatal care for a positive pregnancy experience was published in 2016 with the objective of improving the quality of routine health care that all women and adolescent girls receive during pregnan... more

Download (270)

View PDF (441)

Western Pacific regional framework to end TB: 2021-2030

World Health Organization WHO (2022) C_WHO

his Framework begins with a desired future scenario and considers actions and interventions necessary to get there. It advocates for holistic view to address tuberculosis. The Framework revisits challenges and actions in four layers: TB specific; challenges in health systems that influence TB care; ... more

Download (274)

View PDF (222)

Policy brief: analysing the effectiveness of targeting under AB PM-JAY in India

World Health Organisation (WHO) (2022) C_WHO

This report presents key findings from a study on ‘assessing the effectiveness of targeting mechanisms under PMJAY’. It provides a detailed analysis of potential inclusion and exclusion errors in two select states in India (Haryana and Uttarakhand) to inform National Health Authority’s (NHA) p... more

External Link

Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015

Global Burden of Disease Health Financing Collaborator Network Lancet (2018) CC

Background: Comparable estimates of health spending are crucial for the assessment of health systems and to optimally deploy health resources. The methods used to track health spending continue to evolve, but little is known about the distribution of spending across diseases. We developed improved e... more

External Link

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

Download (272)

View PDF (378)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (157)

View PDF (152)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (660)

View PDF (1706)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (437)

View PDF (660)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (568)

View PDF (849)

India: Guidelines for the Public Private Partnership Model of ART centres

National AIDS Control Organisation (NACO), Government of India (2017) C1

Download (305)

View PDF (432)

WHO technical consultation on oxygen access scale-up for COVID-19

World Health Organization WHO (2021) C_WHO

Download (600)

View PDF (1211)

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (254)

View PDF (497)

Methamphetamine continues to dominate synthetic drug markets

United Nations Office on Drugs and Crime; Global smart (2018) C2

Volume 20, September Global smart update

Download (234)

View PDF (290)

Treat as One. Bridging the gap between mental and physical healthcare in general hospitals

National Confidential Enquiry into Patient Outcome and Death (2017) C1

This NCEPOD report highlights the quality of mental health and physical health care for patients aged 18 years or older with a significant mental disorder who are admitted to a general hospital. The report takes a critical look at areas where the care of patients might have been improved. Remediable... more